Jeffrey Bode PhD

Dr. Jeffrey Bode has been a Professor at The Swiss Federal Institute of Technology (ETH Zürich), since 2010 and is the scientific co-founder of Bright Peak Therapeutics.

Dr. Bode studied Chemistry and Philosophy at Trinity University in San Antonio, Texas. After graduate and postgraduate studies at the California Institute of Technology, ETH Zürich, and the Tokyo Institute of Technology, he joined the University of California, Santa Barbara as an Assistant Professor of Chemistry and Biochemistry. In 2007, he moved to the University of Pennsylvania as an Associate Professor and in 2010 returned to ETH Zürich as a Full Professor. Since 2013, he is also a Principal Investigator at the Institute of Transformative Biomolecules (ITbM) at Nagoya University in Japan. At ETH Zürich, he is a co-founder and Director of Studies for the new undergraduate study program in Biochemistry and Chemical Biology.

Research in the Bode Group has led to innovative new chemical and biological methods for the construction of pharmaceutically relevant compounds, including both small molecules and proteins. His pioneering approaches to synthesizing and tailoring proteins with atomic precision provides access to unique constructs for investigating and controlling biological pathways, including cancer immunotherapy, autoimmune diseases, and ubiquitin biology. He has served as Chair of the Editorial Board for Organic and Biomolecular Chemistry and is currently Editor-in-Chief of Helvetica Chimica Acta and an Executive Editor for the Encyclopedia of Reagents for Organic Synthesis. His research and teaching have been recognized by numerous awards including the Arthur C. Cope Scholar Award (2006), the E. J. Corey Award for Outstanding Young Investigator Award (2010), the Mukaiyama Prize (2018) and selection as a MIT Technology Review TR35 Innovator (2006) and Discover Magazine’s “Best Brains in Science” (2008). In addition to Bright Peak Therapeutics, he is a co-founder of Synple Chem AG and consults or collaborates with numerous pharmaceutical companies.